Headquartered in Lexington, MA·Fiscal year ends December·NASDAQ: CRIS·curis.com
About Curis
Curis, Inc. is a clinical-stage biotechnology company developing emavusertib (CA-4948), an orally available small-molecule inhibitor of IRAK4 and FLT3. It holds an exclusive license to emavusertib through a 2015 collaboration with Aurigene Discovery Technologies Limited. Emavusertib is designed to block the TLR pathway; combined with BTK inhibitors, which block the BCR pathway, it aims for a dual blockade of NF-kB signaling in B-cell malignancies. The company has two active studies. TakeAim Lymphoma is a registrational Phase 1/2 study with ibrutinib in relapsed/refractory primary central nervous system lymphoma (PCNSL); FDA and EMA guidance indicated it could support accelerated approval. TakeAim CLL is a Phase 2 study with zanubrutinib in chronic lymphocytic leukemia. Its AML monotherapy and combination studies are substantially complete, with further AML development dependent on additional funding. Emavusertib has FDA Orphan Drug Designation for PCNSL, AML and MDS, and European Commission orphan designation for PCNSL. The company has had no revenue since selling its Erivedge royalties to Oberland in Q4 2025. It relies on equity financing, including a January 2026 private placement, an August 2026 public offering and an October 2026 private placement, and currently projects cash runway only into Q1 2027. Updated
Thursday's top analyst upgrades and downgrades included AllianceBernstein, AMD, Cisco, eHealth, iHeart Media, Intel, Playtika, ViacomCBS and Williams-Sonoma.
Curis has announced preliminary data from its ongoing early-stage study in patients with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Curis, Inc. is a clinical-stage biotechnology company developing emavusertib (CA-4948), an orally available small-molecule inhibitor of IRAK4 and FLT3. It holds an exclusive license to emavusertib through a 2015 collaboration with Aurigene Discovery Technologies Limited.
What is the CRIS stock price target?
The Wall Street consensus 12-month price target for CRIS is $30.33.